Research lines

• Biomarkers, transplant immunology and cell therapy in renal and pancreatic transplantation.

  Directed by Dr. Fritz Diekmann and Dr. Pedro Ventura

  In the last years we have worked with exosomes, Chimeric antigen receptor-T cells (CAR-Ts), Mesenchymal stem cells (MSC) and their Extracellular vesicles (EVs). Our group has accumulated knowledge in genomic, proteomic and immunological biomarkers that predict transplant outcomes. Moreover, we have contributed to the development of donor-derived cfDNA as a biomarker for solid organ transplant follow-up (kidney, pancreas, uterus) and decision-making tool for treatments of acute rejection.

  Based on this research, we are designing and performing in vitro and in vivo cell therapies in order to prevent and treat organ rejection and improve access to transplant organs for hypersensitized patients.

• New technologies and biomarkers in dialysis

  Directed by Dr. Francesc Maduell

  During the last years we analyzed and improved the quality of dialysis, especially studying vascular calcifications and their possible treatments. Furthermore, we are investigating on new models of uremic toxin purification.

• Pathophisiology and innovative therapies in acute and chronic kidney disease

  Directed by Dr. Luis F Quintana and Dr Miquel Blasco.

  We were studying endothelial dysfunction and complement disorders in the context of chronic kidney disease.

  Furthermore, we have a special interest in biomarkers and innovative therapies in vasculitis and other immunological diseases with renal involvement.

• Artificial intelligence

  Directed by Dr. Ignacio Revuelta

  We are developing predictive AI models that classify patients in terms of their immunological risk and, consequently, their risk of rejection and graft loss. We also apply AI approaches in the pre and peri-transplant setting in order to improve patient selection and management.